P53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer

Nan Yung Hsu, Jeng Yuan Wu, Xiyong Liu, Yun Yen, Chih Yi Chen, Ming Chih Chou, Huei Lee, Ya Wen Cheng

研究成果: 雜誌貢獻文章同行評審

9 引文 斯高帕斯(Scopus)

摘要

p53R2 is a small subunit of ribonucleotide reductase (RR) which has 80% homology to hRRM2 and metastasis suppressing potential. Previous reports suggested that the expression of p53R2 is used as a prognostic factor and chemo-therapy response indicator in several types of cancer. This study aimed to elucidate the association of p53R2 expression and the clinicopathological characteristics of early stage non small cell lung cancer (NSCLC). Immuno histochemistry was conducted on a tissue array including 92 early stage NSCLC samples. Correlations between p53R2 and clinicopathological factors, recurrence/metastasis and outcomes were analyzed. The analyses showed that there was no correlation between p53R2 expression and the clinicopathological factors. Among disease-free patients during follow-up, patients with p53R2(+) had a better outcome than those with p53R2(-) (P=0.022). By using Cox multivariate regression analysis, p53R2 (risk factor 3.801; 95% CI 1.004-9.454; P=0.044) served as a prognostic biomarker in the prediction of the survival rate for NSCLC patients. Detection of the RR subunit p53R2 may therefore be a useful prognostic marker in early stage NSCLC.
原文英語
頁(從 - 到)609-613
頁數5
期刊Oncology Letters
1
發行號4
DOIs
出版狀態已發佈 - 七月 2010
對外發佈

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究

指紋

深入研究「P53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer」主題。共同形成了獨特的指紋。

引用此